Epilepsy combo therapy shows promise in small trial
NCT ID NCT01345058
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding lacosamide (Vimpat) to a low dose of levetiracetam works better than a high dose of levetiracetam alone for controlling seizures. Fifty-six adults with epilepsy who had seizures on low-dose levetiracetam took part. The main goal was to see how many people stayed seizure-free for six months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- lacosamide (Vimpat) and levetiracetam
- What this could lead to
- If successful, this could offer a more effective way to control seizures for people whose current medication isn't working well enough.
- What could go wrong
- This is a small, completed Phase 3 trial with only 56 participants, so results may not apply to everyone. Adding another drug also increases the risk of side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPILEPSY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can MRI reveal the Brain's response to deep brain stimulation?
- Can community hospitals in zambia master severe disease care?
- Can mindfulness rewire the mind to lift depression in epilepsy?
- A break from seizure pills: could less medication mean better living?
- Can invisible electric fields quiet the Brain's seizure signals?
- Can a new drug tame severe childhood epilepsy?